Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Methylthioninium chloride - TauRx

Drug Profile

Methylthioninium chloride - TauRx

Alternative Names: Methylene blue - TauRx; MTC; Rember; TRx-0014; TRx-014

Latest Information Update: 12 Nov 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TauRx Therapeutics
  • Developer TauRx Therapeutics; University of Aberdeen
  • Class Antidementias; Antiparkinsonians; Phenothiazines; Small molecules
  • Mechanism of Action Synuclein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 12 Nov 2012 Discontinued - Phase-II for Alzheimer's disease in Singapore (PO)
  • 12 Nov 2012 Discontinued - Phase-II for Alzheimer's disease in United Kingdom (PO)
  • 12 Nov 2012 Discontinued - Preclinical for Parkinson's disease in Singapore (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top